Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development

Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development

We present a new strategy for self-adjuvanting vaccine development that has different types of covalently-linked immunostimulants as the carrier molecule. Using Tn antigen as the model, a three-component vaccine (MPLA-Tn-KRN7000) containing the TLR4 ligand MPLA and the iNKT cell agonist KRN7000 was...

Full description

Bibliographic Details
Main Authors: Deying Yang, Xiang Luo, Qinghai Lian, Lingqiang Gao, Chengxin Wang, Xiaoxiao Qi, Rong Zhang, Zhongqiu Liu, Guochao Liao
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Cancer vaccine
Tn antigen
MPLA
KRN7000
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522002507

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522002507

Similar Items